Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 6
1982 5
1983 2
1984 4
1985 5
1986 10
1987 8
1988 12
1989 11
1990 13
1991 11
1992 16
1993 11
1994 7
1995 16
1996 11
1997 15
1998 14
1999 15
2000 14
2001 26
2002 26
2003 55
2004 52
2005 71
2006 55
2007 73
2008 89
2009 93
2010 79
2011 120
2012 135
2013 158
2014 203
2015 189
2016 202
2017 229
2018 235
2019 277
2020 336
2021 447
2022 289
Text availability
Article attribute
Article type
Publication date

Search Results

3,260 results
Results by year
Filters applied: . Clear all
Page 1
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, Traugh N, Zeng Z, Zhang Y, Li Z, Zhang B, Fu J, Xiao T, Li W, Meyer CA, Chu J, Jiang P, Cejas P, Lim K, Long H, Brown M, Liu XS. Wang X, et al. Among authors: gu ss. Cell. 2021 Oct 14;184(21):5357-5374.e22. doi: 10.1016/j.cell.2021.09.006. Epub 2021 Sep 27. Cell. 2021. PMID: 34582788
Urticarial vasculitis.
Gu SL, Jorizzo JL. Gu SL, et al. Int J Womens Dermatol. 2021 Jan 29;7(3):290-297. doi: 10.1016/j.ijwd.2021.01.021. eCollection 2021 Jun. Int J Womens Dermatol. 2021. PMID: 34222586 Free PMC article. Review.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Among authors: gu s. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F. Qin S, et al. Among authors: gu s. J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29. J Clin Oncol. 2021. PMID: 34185551 Clinical Trial.
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.
Duan J, Wang Z, Duan R, Yang C, Zhao R, Feng Q, Qin Y, Jiang J, Gu S, Lv K, Zhang L, He B, Birnbaumer L, Yang S, Chen Z, Yang Y. Duan J, et al. Among authors: gu s. Hepatology. 2022 Jan;75(1):140-153. doi: 10.1002/hep.32148. Epub 2021 Nov 27. Hepatology. 2022. PMID: 34510514
3,260 results